Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Liposomal Amphotericin B in Liver Transplant Recipients With Invasive Mold Diseases
NCT07725874Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Aug 2026
- Primary completion
- May 2028
01
Overview
Open-label, single-arm trial of liposomal amphotericin b in Invasive mold disease (IMD), sponsored by Beijing Friendship Hospital. Primary endpoint: Safety profile of liposomal amphotericin B at 6 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
liposomal amphotericin b
03
Conditions
Invasive mold disease (IMD)
Beyond the preview
Go deeper on NCT07725874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07725874.